March 2015 – The CenterWatch Monthly : PDF
Novo Nordisk, Takeda, Servier, Celgene among top sponsors
Relationships between drug sponsors and investigative sites have become more effective during the past two years, according to a new CenterWatch survey, as the initiatives top sponsors have implemented in recent years to address site burdens—such as increased protocol complexity and insufficient study support—are beginning to have a positive impact.
Patient reported outcomes take center stage
A growing number of clinical trials now are going beyond conventional randomized control measurements to collect self-reported outcomes from patients—focusing on improving patients’ involvement by including their perspectives throughout the drug development process. But while interest in developing and applying patient-reported outcomes (PROs) across the drug development and post-market spectrum is growing—among sponsors, clinicians, payers, regulators and patients—progress has been slow.
Also in this issue:
- Going native: Stepping back from the functionality cliff
- Medical outcome trials: The best evidence for the best products
- Regulatory Update
- Month in Review
- FDA Actions
- Study Lead Opportunities
- New Drugs in the Pipeline